Neurodyn Life Sciences Inc

Neurodyn Life Sciences Inc. is a developer and incubator focused on the identification, preclinical validation, and development of natural bioactives and granulin-based therapeutic candidates for neurological diseases and brain health. The company operates a wholly owned, neurology-focused contract research organization (CRO) to generate efficacy data and support translational activities, including toxicology and regulatory submissions. Neurodyn functions as an incubator that matures projects before licensing them to commercial partners or spinning them out into independent business units. One of its notable developments includes Cerbella, a consumer-facing brain health brand featuring a formulation of bioactive compounds.

This research and development work is critical for addressing the significant unmet needs in treating neurodegenerative conditions and promoting general cognitive health. By leveraging proprietary research into natural bioactives and advanced delivery systems, the company seeks to improve the safety and efficacy of therapeutic options for patients. Neurodyn has a track record of advancing assets through development pipelines, such as the licensing of its Galantamine prodrug technology to Alpha Cognition Inc., which subsequently received FDA approval for the treatment of Alzheimer’s dementia. The company collaborates with various public and private entities, including receiving support from government research programs to enhance its formulation and stabilization technologies.